NovoCure

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NovoCure and other ETFs, options, and stocks.

About NVCR

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division.

CEO

Frank Leonard

CEOFrank Leonard

Employees

1,605

Employees1,605

Headquarters

St. Helier, Jersey

HeadquartersSt. Helier, Jersey

Founded

2000

Founded2000

Employees

1,605

Employees1,605

NVCR Key Statistics

Market cap

1.75B

Market cap1.75B

Price-Earnings ratio

-10.09

Price-Earnings ratio-10.09

Dividend yield

—

Dividend yield—

Average volume

1.95M

Average volume1.95M

High today

$15.68

High today$15.68

Low today

$14.96

Low today$14.96

Open price

$15.44

Open price$15.44

Volume

1.41M

Volume1.41M

52 Week high

$18.92

52 Week high$18.92

52 Week low

$9.82

52 Week low$9.82

Stock Snapshot

The current NovoCure(NVCR) stock price is $15.15, with a market capitalization of 1.75B. The stock trades at a price-to-earnings (P/E) ratio of -10.09.

As of 2026-06-30, NovoCure(NVCR) stock has fluctuated between $14.96 and $15.68. The current price stands at $15.15, placing the stock +1.3% above today's low and -3.4% off the high.

The NovoCure(NVCR)'s current trading volume is 1.41M, compared to an average daily volume of 1.95M.

In the last year, NovoCure(NVCR) shares hit a 52-week high of $18.92 and a 52-week low of $9.82.

NVCR News

TipRanks 10h

Novocure’s Optune Pax Secures CE Mark for Pancreatic Cancer

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

TipRanks 10h

Novocure announces Optune Pax received CE Mark

Novocure (NVCR) announced that Optune Pax has received CE Mark for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, c...

Simply Wall St 3d

NovoCure Is Up 8.1% After TRIDENT Shows No Survival Gain From Earlier TTFields Start - simplywall.st

...

Analyst ratings

71%

of 7 ratings

Buy

71.4%

Hold

28.6%

Sell

More NVCR News

Simply Wall St 5d

NovoCure Could Be 42% Undervalued On Mixed TRIDENT Trial Results

NovoCure (NVCR) stock is in focus after the company reported topline Phase 3 TRIDENT data showing no statistically significant overall survival benefit from ear...

The Motley Fool 6d

HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026?

Investors choosing between high-growth healthcare innovators must weigh specialized diagnostics against therapeutic platforms. Choosing between HeartFlow Inc. (...

People also own

Based on the portfolios of people who own NVCR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.